MSDC-0160 is a novel, clinical-stage drug candidate originally developed for . It is the prototype of a new class of insulin sensitizers called mTOT Modulators (Mitochondrial Target of Thiazolidinediones). Unlike first-generation insulin sensitizers like pioglitazone, MSDC-0160 is PPAR
MSDC-0160 works by selectively binding to and inhibiting the , a protein complex in the inner mitochondrial membrane. msdc 0160 buy
In preclinical models, MSDC-0160 protected dopaminergic neurons, improved motor function, and reduced neuroinflammation. the main gateway for carbohydrate metabolism.
It helps cells maintain "trash removal" systems (autophagy), preventing the toxic buildup of proteins like -synuclein . In preclinical models
It may prevent or reverse dyskinesia (involuntary movements) caused by standard Parkinson's medications. 2. Alzheimer’s Disease (AD) MSDC-0160 - Metabolic Solutions Development Company
-sparing , meaning it avoids many common side effects like weight gain and fluid retention. Core Pharmacology and Mechanism
It blocks the entry of pyruvate into the mitochondria, the main gateway for carbohydrate metabolism.